binary-catalyst-biotech theme · 48 dossiers

Two of three lead binaries (SPY001, SPY002 anti-TL1A) printed potential best-in-class; the stock absorbed a ~$399.7M director-fund block sale and sits back near its ~$102 ATH (~$95). Next legs — SPY003 IL-23 Part A (guided mid-2026,…

Single-asset UC biotech; the pivotal binary already fired (June 29 Phase 3 maintenance: ~50% Week-44 remission vs 10.4% placebo), the ~$920M raise cleared at $125, and 13 analysts caught it after the +36% gap. Now faded back to the…

Best-in-class oral TYK2 story sitting near 52-week highs (~$28) as the market waits on the Q3 2026 LUMUS Phase 2b lupus topline — the binary that either re-rates envudeucitinib into a multi-billion indication or caps it as a psoriasis-only…

Single-asset binary: Phase 3 LUCIDITY topline for avexitide in post-bariatric hypoglycemia is guided for late August/early September 2026 (reaffirmed 2026-08-06), while the stock has run 54.9% in three months to within 5.7% of its 52-week…

Precision-psychiatry re-rate (~10x off $2.85) re-armed on 2026-07-13 — a successful FDA meeting cleared an additional ALTO-207 monotherapy Phase 3 in TRD, funded same-day by a $100M raise at $26.48. Narrative refreshed, but every data…

Rumor confirmed and cashed: Eli Lilly is acquiring AtaiBeckley (announced 2026-07-16) for $6.75/share cash plus up to $2.50 CVR tied to BPL-003/VLS-01 milestones. Shares gapped to ~$7.20 and desks cut to Hold en masse — momentum is dead,…

De-rate reversal off the $7.48 Nov-CRL low has stalled near $14 after peaking ~$16 in early July; the opakalim epilepsy pivotal (RISE3) topline is unscheduled 2H-26, sell-side is turning cautious (BofA Underperform $11), and a dilution…

Lifyorli oncology launch (approved 2026-03-25, NCCN preferred) re-accelerated the tape to fresh 52-week highs near $92, and the 2026-06-17 Cushing's relacorilant resubmission (~Dec PDUFA) adds second-approval optionality. But a fresh entry…

The 2026-08-06 Q2 update pushed the registrational PTCL interim from late 2026 to a Q1 2027 futility analysis that publishes no efficacy data, and set AD Phase 2 topline at Q3 2027 — the binary clock this name traded on is now empty until…

Definium re-accelerated off the June Phase 3 MDD win: a Wells Fargo initiation at $68 (7/27) and Piper's $75 (8/7) carried it to $46.14, 4.8% under the 52wk high. The leg being bought is DT120 as a multi-indication CNS franchise — and the…

The June–July re-rate has run into an empty calendar. The 2026-08-03 Q2 update pushed DT-168 FECD data to 2027 and re-cut RESTORE-FA to a 10-patient 12-week cohort with blood FXN protein as the primary efficacy endpoint, moving the next…

Post-crash story reset: 2026-07-13 updated ERAS-0015 Phase 1 data (57% uORR at 32 mg in 2L+ KRAS G12X pancreatic, n=7) plus 2027 pivotal plans, immediately monetised via a 31,428,572-share offering at $17.50 on 2026-07-14. Funded, but the…

Post-launch broken-momentum hematology name: RYTELO 2L lower-risk MDS ramp is real but decelerating ($51.8M Q1 net rev, +31% YoY) while price holds near its $1.04 52-week low, below every major MA. The only live re-rate is the…

Post-dilution CNS microcap re-firing with the psychedelic cohort (ATAI, CMPS all moving 2026-07-16) after a June social-velocity blowoff and a 10.3M-share secondary at $4.85. Both covering shops cut targets in July while holding Buy. No…

Post-Parkinson's-failure microcap, now a single-asset PAH story (IKT-001 imatinib prodrug). IMPROVE-PAH Phase 3 only began enrolling 2026-04-07, so topline is 2027-2028 and there is no near-term binary. Stock ~$2.23 trades near its ~$200M+…

Dilution overhang answered with debt: the 2026-07-16 Oxford amendment lifted the facility to $500.0M and funded $100.0M immediately, leaving the ~14.67M share count intact but the balance sheet levered into a nine-month wait for the…

Single-asset MASH binary: lanifibranor's NATiV3 Phase 3 topline (Q4 2026) is the whole equity. The June 2 refinancing cleared the funding overhang (runway into early Q1 2028) and Cantor initiated Overweight July 17. Stock coils on the…

Fuel-reversion bull leg broke: Brent re-spiked to ~$86 (Jul 17) on renewed Mideast conflict, reversing the sub-$73 tailwind the whole trade needed. Raymond James (Jul 6) cut to Underperform flagging a Chapter 11 that wipes equity; $9.3B…

ABC-platform redemption arc: after the 2022 DAZZLE wet-AMD miss took KOD to $4.60, back-to-back positive Phase 3 diabetic-retinopathy readouts (GLOW1, GLOW2) re-rated it ~9x. The September 2026 DAYBREAK wet-AMD topline is the binary —…

Squeeze leg has stalled: Morgan Stanley's 2026-07-06 Underweight/$15 reinit broke the one-way upgrade cluster and knocked the stock -5.9% on 07-08. Price ~$17.18 still holds above the 50- and 200-day, but with the sell-side now two-sided…

Single-asset schizophrenia story re-rating on the 2026-07-22 pull-forward of NOVA-2 Phase 3 topline to H1 2027 plus a $150M crossover round at $34.94 on 2026-07-28. Price closed $48.00 on 2026-08-07 — above every published target ($45 HCW,…

Single-asset FA binary: nomlabofusp's rolling BLA for accelerated approval is live, but the 2026-06-29 open-label data carried an anaphylaxis signal (10 of 43 patients, ~23%) that turned the filing into a ~17% selloff. Shares drift near…

The oncology-pivot re-rate (0.55 to 8.00 in twelve months) has stalled: RLMD lost 10.5% on 2026-07-16 and another 4.0% on 2026-07-17 to $5.24, unwinding the Russell-inclusion bid with no dated NDV-01 catalyst before end-2026. Story intact,…

Post-interim re-rating has fully decayed: $4.61 on 2026-07-17 vs the $5.14 late-June high, with no dated event between here and the upLIFT full topline in 2H-2026. A binary rare-disease name in its dead zone — the 6/8 responder signal is…

Type-1-diabetes functional-cure narrative: UP421's no-immunosuppression islet transplant is still producing insulin at 14 months (n=1), de-risking SC451's IND guided "as early as 2026." Rare-disease cell therapy is accelerating, but the…

A record short squeeze (~32% of float) and buyout speculation, now joined by sell-side PT hikes (Alliance Global $10→$25, Jul 17), have carried SLS to a $16 test and back to ~$13; the defining Phase 3 REGAL overall-survival readout stays…

Single-asset ivonescimab binary sitting $1.26 above its $12.55 52-week low with going-concern language on the record. The narrative leg is dead but the funding question changed shape: co-CEO Duggan bought 3.81M shares at $13.12 on Jun 12…

Single-asset binary now inside its own catalyst window: the STRO-004 (DAR8 Tissue Factor exatecan ADC) Phase 1 readout was guided "mid-2026" and that window is expiring undated. Price has gone flat at ~$29.7 for four weeks after the June…

Clinical binary printed clean (2026-06-22: 100% milestone response N=12, zero treatment-related SAEs) but the next catalyst slipped to H1 2027 — pivotal six-month interim AND FDA BLA-pathway feedback both guided to the first half of next…

June's volume-backed reclaim to $10.03 failed to extend — $9.43 on Jul 17, -5.3% on the week, with short interest rising to 11.72% of float as shorts pressed the fade. Structure holds above the 50-DMA near $8.71, but nothing hard is dated…

Royalty-collector-to-owned-pipeline pivot; XmAb819 ccRCC data at ESMO (Oct 23–27) is the real binary but ~90 days out. Stock ran $6.92→$17.47 to near 52-week highs on pipeline optimism while royalty revenue collapses (Q1 $4.5M vs $32.7M…

Both Phase 2 trials (TibuSHIELD/HS, TibuSURE/SSc) are now fully enrolled and fresh William Blair + Chardan bull notes landed in early July, but the enrollment-momentum leg has stalled — 2026-07-17 volume ran ~82% below average and price is…

The June patent re-rating fully reversed: EMA's CHMP issued a negative opinion on arimoclomol's EU application 2026-07-24 (efficacy not proven), and ZVRA gapped ~24% to the high-$9s, cutting through the $11.50 base. EU expansion is now…